Biopharmx Corp (NYSEMKT:BPMX), which happens to be a specialty pharmaceutical provider focusing majorly in the development of a wide range of products for the dermatology market has today gone ahead to make public its success in the achievement of a primary endpoint in its phase 2b clinical trial evaluating BPX-011, the first completely solubilized topical minocycline gel product candidate that will according to sources go a long way to help a lot of people face out moderate-to-severe acne.

This as a matter of fact comes as great news to a lot of people who have over time been struggling with the associated condition. The various cross-cutting developments that are happening as a result of research as well as the implementation of the latest in terms of technology are transforming lives, and there is no doubt about that!

From the topline results for the study’s primary endpoint, the company made its observations. It reported some statistically major reductions in non-nodular inflammatory acne lesions when compared to vehicle and that is as a matter of fact in relation to the 1 percent and 2 percent doses of BPX-01.

The co-founder and president of BioPharmX, Anja Krammer while addressing a press conference said, “These results represent a major milestone for the company and offer the potential of BPX-01 as the first topical gel minocycline for moderate-to-severe acne, optimizing safety and efficacy of a proven antibiotic for this condition to millions of patients e look forward to sharing detailed phase 2b data with the investor and medical communities over the coming months.”

The company is set to be unveiling its comprehensive results from the phase 2b study at an event for the investment community which will of course take place in New York the following month. BioPharmX is expects to forward the data for publication in a peer-reviewed medical journal as well as for presentation at an upcoming medical conference.

board-certified dermatologist at Dermatologist Consulting Services in High Point, North Carolina who is at the same time the principal investigator in the phase 2b trial while making a statement outlined, “These positive results are very encouraging and bring hope to the dermatologic community, but most importantly to the patients who suffer physically, emotionally and psychologically from moderate-to-severe acne — that a new minocycline targeted topical gel will offer treatment for this condition,”

A lot more is on the way, but the associated impact is something we just have to wait and see.